当前位置： SCI文献检索 > PEDIATRIC BLOOD & CANCER期刊下所有文献 > Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: a North American perspective.

Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: a North American perspective.

Abstract：

BACKGROUND:Anthracycline agents are used for treatment of acute myeloid leukemia (AML) but may cause late-onset cardiomyopathy. Current frontline therapy for AML in North America, as reflected in the approach of the Children's Oncology Group (COG) and other pediatric consortia, is adapted from the anthracyline-intensive Medical Research Council (MRC) regimen. The purpose of this study was to describe early post-treatment cardiac function as a potential indicator of acute and long-term risk associated with this approach. PROCEDURE:A multi-center retrospective cohort analysis was conducted of AML survivors diagnosed from 2004 to 2009 and treated with MRC-based regimens. Change in left ventricular shortening fraction (LVSF) on echocardiogram was determined from baseline to latest post-treatment/pre-relapse value; associations with potential predictors were examined. RESULTS:This cohort of pediatric survivors (n = 52) was assessed at a median interval of 13 months from end of treatment. Mean cumulative anthracycline dose was 339 ± 14 mg/m(2) . Mean baseline and post-treatment LVSF were 39.3 ± 0.8% and 35.4 ± 0.9%, respectively; mean percent change for individuals was -8.4 ± 2.8% (P < 0.001). Cardiac-directed medications were initiated in four patients (7.7%). Decline in LVSF was significantly associated with cumulative anthracycline dose, increasing BMI and Hispanic ethnicity. CONCLUSION:Early, significant decline in LVSF was observed following treatment with these MRC-based regimens. Elevated BMI and Hispanic ethnicity were identified as new independent risk factors. Children and adolescents so treated are at substantial risk for late-onset cardiomyopathy, require monitoring with annual echocardiogram per current COG survivorship guidelines, and are good candidates for appropriate cardioprotection strategies.

journal_name

Pediatr Blood Cancer

journal_title

Pediatric blood & cancer

authors

Orgel E,Zung L,Ji L,Finklestein J,Feusner J,Freyer DR

doi

10.1002/pbc.24498

subject

Has Abstract

pub_date

2013-09-01 00:00:00

pages

1528-33

issue

eissn

1545-5009

issn

1545-5017

journal_volume

pub_type

临床试验,杂志文章,多中心研究

在线工具

Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: a North American perspective.